GlassScriptPhysician profile
Jorge Gil
NPI 1639425630
$8,473.03
in general payments reported to CMS, 2019-2025
26 companies · $1,480 in 2025
The $1,480 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,545 · 2022: $1,798 · 2023: $2,049 · 2024: $1,602 · 2025: $1,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,041 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,040.82 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,657.32 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,529.16 | 2021-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $762.06 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $711.64 | 2021-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $462.96 | 2021-2025 | Entyvio, Eohilia |
| Cumberland Pharmaceuticals, INC. | $349.79 | 2021-2023 | Kristalose |
| Phathom Pharmaceuticals, INC. | $324.50 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $290.93 | 2021-2024 | Linzess |
| Genzyme Corporation | $275.01 | 2022-2025 | |
| Redhill Biopharma INC. | $258.59 | 2021-2023 | Talicia |
| Intercept Pharmaceuticals, INC. | $230.76 | 2021-2025 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $225.44 | 2021-2023 | |
| Madrigal Pharmaceuticals | $225.43 | 2024-2025 | Rezdiffra, Resmetirom |
| Evoke Pharma, INC. | $220.86 | 2023-2025 | Gimoti |
| Pfizer INC. | $204.40 | 2023-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $161.12 | 2025 | Wegovy |
| Janssen Scientific Affairs, LLC | $119.70 | 2022 | |
| Braintree Laboratories, INC. | $101.29 | 2022-2024 | Sutab |
| Regeneron Healthcare Solutions, INC. | $94.48 | 2024-2025 | Dupixent |
| Exact Sciences Corporation | $81.86 | 2023-2024 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $57.06 | 2021-2022 | |
| Lilly USA, LLC | $43.07 | 2023-2025 | Omvoh |
| Boston Scientific Corporation | $33.66 | 2023 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Fresenius Kabi USA, LLC | $21.27 | 2023 | |
| Vivus LLC | $17.85 | 2021 | |
| Merck Sharp & Dohme LLC | $12.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Gil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.